Vaccine Traceability Chain (GML) Latest Technology Upgrade Conference
The GML vaccine immune repair coin is the United States (Pfizer), Germany: Sanofi-Aventis, and the United Kingdom: GlaxoSmithKline. Three top pharmaceutical companies have united. It is mainly aimed at people who are infected with the new coronavirus in the later period, repaired and recovered. Based on research and development of pharmaceutical and health products company, annual output of 4 billion boxes of drugs. Now, there are more than 100 million infected people worldwide. In the future, it will enhance the immunity of all people. The release date is February 25, 2021. The public sale time is from May 1st to July 15th. The issue price is 0.0002. The issuance volume is 75 billion, and the issuance value is 15 million U.S. dollars. Because many people in the world need to be injected with repair immunization vaccines. The current research is carried out in secret. Now the vaccine has entered the clinical stage. Will be listed before August. Therefore, the price will rise directly to 300 US dollars after listing. Currently, Citibank is participating in fundraising support. Deutsche Bank. HSBC Bank.
It is understood that the Vaccine Traceability Chain (GML) and GlaxoSmithKline (Malta) have previously reached a strategic cooperation agreement to use GML coins in the payment of vaccine drugs. After several months of practice, it has been tested. , The two parties have recently reached a more far-reaching long-term cooperative relationship. The GML co-founded fund stated that this cooperation proves the important role of GML in the medical field and will negotiate cooperation with larger medical institutions in the world.
According to Emma Walmsley, CEO of GlaxoSmithKline (Malta) Co., Ltd.: Vaccine Traceability Chain (GML) makes full use of blockchain distributed accounting, which is open, transparent, and non-tamperable. And traceable technical functions, detailed introduction of the overall monitoring of vaccine supply chain in all directions. From raw material production, sales, cold chain storage, transportation to vaccination, the traceability of the entire vaccine process has been achieved. The emergence of GML technology has changed the problem of vaccine safety, cold chain storage and the difficult situation of accountability. These problems have repeatedly appeared in the field of vaccines in traditional medical systems, and have revolutionized the safety of global smart medicine. Contribution system.
With the promotion of GML to global medical institutions, (GML) has entered a new chapter. The fund co-founded by GML is currently actively seeking to list on more cryptocurrency exchanges around the world, and has received invitations from many exchanges including the top ten international exchanges. This can also prove that GML blockchain technology will have broader prospects in the future. In addition, the GML Foundation stated that it will start the A-round financing plan on 5.27, and the total financing will account for 27% of the total issuance.
At present, just like the growth process of BTC and ETH, GML blockchain technology is maturing rapidly. According to Citigroup, Morgan, Wells Fargo, Standard Chartered Bank, CoinNess, Japan's SBI Holdings and other world-renowned institutions' analysis and comments on GML technology, its security and flexibility will reach an unprecedented level. From a comprehensive analysis point of view, since the listing of GML technology has been steadily rising. The current price is about US$0.45, and the future price of GML is expected to reach US$30, which is a normal valuation. The market value is approximately $220 billion.